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ABSTRACT  30 
(MAX. 250 WORDS) 31 
Background and purpose 32 
To assess the potential of composite minimax robust optimization (CMRO) compared to planning 33 
target volume (PTV)-based optimization for head and neck cancer (HNC) patients treated with 34 
volumetric modulated arc therapy (VMAT). 35 
Materials and methods 36 
Ten HNC patients previously treated with a PTV-based VMAT plan were studied. In addition to the 37 
PTV-plan a VMAT plan was created with CMRO. For both plans an adapted planning strategy was 38 
also investigated, including a plan adaptation during the third week of treatment. The PTV-plans and 39 
CMRO-plans (adapted and non-adapted) were evaluated by means of the estimated actually given 40 
dose (EAGD). Therefore, the dose was calculated on daily acquired CBCTs, mapped onto the planning 41 
CT and accumulated. The plans were compared by dosimetric parameters and normal tissue 42 
complication probabilities (NTCPs) for tube feeding dependence, grade 2-4 dysphagia and 43 
xerostomia. The accuracy of CBCT-based dose accumulation was further quantified by comparisons 44 
of dose accumulation on weekly verification CTs. 45 
Results 46 
On average, CMRO significantly increased (1.5 Gy) the D98% of the EAGD to the clinical target volume 47 
and significantly decreased the mean dose of the ipsilateral parotid (2.8 Gy), inferior pharynx 48 
constrictor muscle (0.7 Gy) and the oral cavity (0.8 Gy). This translated into significantly reduced 49 
NTCP of tube feeding dependence (0.9%) and xerostomia (2.8%). The differences in EAGD derived 50 
from evaluation CTs or CBCTs were minimal. 51 
Conclusion 52 
Minimax robust optimization led to improved target coverage and dose reduction in organs at risk in 53 





The primary goal of radiotherapy is to adequately treat the clinical target volume (CTV) with a 57 
uniform dose. The CTV is however subject to geometrical variations and setup uncertainties. The 58 
traditional approach to avoid underdosage during the fractionated treatment course is to apply a 59 
planning target volume (PTV) margin around the CTV [1–3]. This approach should lead to adequate 60 
PTV coverage on the planned dose distribution and adequate coverage of the CTV during the 61 
treatment course. 62 
The use of a PTV margin is based on the assumption that the dose distribution is invariant. However, 63 
setup errors and geometrical variations affect the shape of the dose distribution, especially in the 64 
vicinity of density gradients. PTV-less optimization approaches have been described in literature that 65 
provide a superior balance between tumor control rate and normal tissue toxicity. These 66 
optimization approaches are referred to as robust optimization [4–10]. 67 
Two approaches to robust planning optimization have been introduced: probabilistic planning and 68 
minimax optimization [11,12]. The probabilistic approach consists of optimizing the expectation 69 
value of objectives based on an a priori probability density function of geometric errors. Recently, 70 
Witte et al. investigated the potential clinical benefit of PTV-less probabilistic planning in a spherical 71 
phantom [10]. They demonstrated that an indentation of the 95% dose level by one third of the 72 
margin size at a strictly uniform dose distribution at prescription level is feasible without sacrificing 73 
tumor dose confidence. Fontanaroza et al. demonstrated probabilistic planning for IMRT in head and 74 
neck cancer (HNC) patients and found improved organ-at-risk (OAR) sparing as compared to PTV-75 
based plans, with comparable CTV coverage [5]. The minimax robust optimization approach instead 76 
optimizes the objective value in the worst-case based on a positioning inaccuracy in different 77 
directions. In contrast to the probabilistic approaches in which a probability distribution is needed, 78 
the minimax robust optimization approach only requires information about the scenarios to include. 79 
Fredriksson et al. proposed an implementation of minimax robust optimization which aims to 80 
optimize the objective function of the physically realistic composite worst-case scenario [13]. In a 81 
recent study, this composite minimax robust optimization (CMRO) was found to give a sharper dose 82 
fall-off than other implementations[14].  83 
CMRO was previously evaluated in static and dynamic phantoms [15,16]. Both studies demonstrated 84 
improved target uniformity compared to PTV-based planning methods, especially near 85 
heterogeneous density regions. Since these phantom studies have demonstrated great potential also 86 
for OAR sparing, we evaluated the CMRO in detail for adaptive photon therapy in HNC patients.  87 
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The aim of this study was to assess the benefit of CMRO compared to PTV-based optimization in 88 
HNC patients treated with VMAT in terms of CTV coverage and dose to non-target tissues.  89 
MATERIALS AND METHODS 90 
Patients and treatment 91 
The study population consisted of ten patients with stage II-IV squamous cell HNC with various 92 
tumor locations: paranasal sinus (2); nasopharynx (3); glottic larynx (1); hypopharynx (1); oropharynx 93 
(3). The tumor stages varied between T1-4N0-2M0. All patients reported their xerostomia as ‘None’ 94 
or ‘a bit’ according to the EORTC QLQ-H&N35 and their weight loss prior to treatment was none (5) 95 
or 1-10% (5). None of the patients had a percutaneous endoscopic gastrostomy tube before start of 96 
treatment. 97 
All patients were previously treated with a simultaneous integrated boost technique consisting of a 98 
prescription of 70.00 Gy to the therapeutic CTV and 54.25 Gy to the prophylactic CTV in 35 fractions 99 
using VMAT [15]. The PTVs were created using a 5.0 mm uniform expansion of their respective CTVs. 100 
Plans were optimized aiming at V95%≥98% of the PTV while limiting the maximum spinal cord dose 101 
to 54.00 Gy and the maximum brain dose to 60.00 Gy. The mean dose to the parotid glands and 102 
swallowing muscles were reduced as much as possible. All clinical plans were created by a 103 
dosimetrist specialized in HNC planning. Patients were immobilized using an individualized neck 104 
cushion and a 5-points mask.  Online patient positioning verification was performed daily using CBCT 105 
imaging. In addition, verification CTs were acquired on a weekly basis outside the treatment room. In 106 
total 350 CBCTs and 70 verification CTs were analyzed. 107 
Treatment plan optimization 108 
Planning was performed in the RayStation (RaySearch Laboratories AB, Stockholm, Sweden) 109 
treatment planning system (TPS). Clinical PTV-plans were created in version 5.0 and its adjustments 110 
in version 4.99, which is the research build of the same version. The clinical PTV-plan was further 111 
optimized to create a reference ‘PTV-plan’. In addition, a copy of the clinical PTV-plan was used to 112 
create the CMRO-plan in which only the target objectives were changed into their respective CTVs. 113 
Next, the CMRO-plan was optimized using the CMRO algorithm [13]. The CMRO algorithm minimized 114 
the cost function of the worst out of seven scenarios which consisted of the nominal scenario and 115 
5.0 mm shifts of the isocenter in the planning CT in the lateral, longitudinal and transverse 116 
directions. Each plan was optimized with the same objective weights for 200 iterations or when an 117 
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optimal solution (tolerance <1e-5) was reached. All plans had an isotropic dose grid resolution of 3.0 118 
mm. 119 
To ensure equal target coverage, the CMRO-plan and PTV-plan were normalized such that the D98% 120 
of the CTVs received at least 95% of the prescribed dose in the voxel-wise minimum dose. Since 121 
CMRO is referred to as margin-less planning, the PTV could not be used for plan normalization. 122 
Moreover, Harrington et al. illustrated that the voxel-wise minimum dose can be interpreted 123 
similarly to the PTV dose of the nominal plan [16]. The voxel-wise minimum dose was derived from 124 
14 perturbed scenarios by rigidly shifting the isocenter in the planning CT with 5.0 mm in the lateral, 125 
longitudinal and transverse directions and their diagonals. The voxel-wise minimum dose 126 
distribution was then derived as a composite of the minimum dose voxels of all scenarios. This 127 
approach is described in more detail in a previous study [17].  128 
CBCT dose calculation, mapping and accumulation 129 
The workflow for simulating the treatment course to calculate the EAGD is shown in figure 1. 130 
Deformable image registration was performed between each CBCT and planning CT with the 131 
algorithm implemented in the TPS and previously described by Weistrand et al. [18]. In most cases, 132 
the field-of-view (FOV) of the CBCTs did not capture the shoulders and cranial end of the skull. In 133 
these cases, the patient external was mapped from the planning CT to the CBCT. Next, the density of 134 
the volume inside the external, but outside the CBCT’s FOV was assigned a density of 1.00 gcm-3. The 135 
dose of the PTV- and CMRO-plans was recalculated on a segmented CBCT. Segmentation was based 136 
on the TPS’ default settings. In the last step, the dose distributions of all CBCTs were mapped to the 137 
planning CT and summed to get the EAGD.  138 
Plan adaptations 139 
To investigate CMRO in an adaptive setting, we adapted both the PTV-plan and CMRO-plan after 140 
three weeks of treatment if the sum of the three normal tissue complication probabilities (NTCP) 141 
under investigation (see subsection below) increased by +2.5% for the PTV-plan or that the CTVs 142 
were underdosed (i.e. D98%<95%) for the PTV-plan. Plans were adapted by re-optimizing the dose on 143 
the verification CT using the PTV-based optimization for the PTV-plan and CMRO for the CMRO-plan. 144 
Hence, the plan quality was assessed from the EAGD in terms of target coverage, OAR dose and 145 
NTCPs. The EAGD of the adapted treatment schedule was derived from the dose of the first 15 146 
fractions using the nominal plan and the remaining fractions using the dose of the adapted plan.  147 
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CBCT-based dose accumulation validation 148 
Dose re-calculations on the verification CTs were used to validate the accuracy of the EAGD derived 149 
from CBCTs. This, together with dose re-calculations on two different sets of weekly CBCTs were 150 
used to estimate the difference in EAGD due to the use of CBCTs instead of verification CTs. 151 
Analysis 152 
The CMRO-plans were compared against the PTV-plans using dosimetric parameters of the EAGD of 153 
the CTVs and OARs. The investigated OARs reflected those used in our clinical practice. Target 154 





where 𝑉intersect is the absolute volume of the CTV that received 95% of the prescribed dose and 𝑉CTV 156 





 where Dp is the prescribed dose to the target [3]. To derive the HI of the prophylactic CTV the 158 
primary CTV (+5.0 mm) was excluded from it. In addition, all plans were evaluated by NTCP values 159 
for xerostomia [20], grade 2-4 dysphagia [20], and tube feeding dependence [21]. 160 
A paired Wilcoxon signed-rank test was used to calculate two-tailed p-values (R-Project 3.5.1, 161 
Vienna, Austria). The statistical significance was determined after accounting for multiple testing 162 
using Bonferroni’s correction [22]. Differences were considered statistically significant if p < 0.005 (α 163 
= 0.05/10 structures) for OAR doses, p < 0.008 (α = 0.05/6 parameters) for target coverage and p < 164 
0.017 (α = 0.05/3 NTCPs) for NTCPs. 165 
RESULTS 166 
The difference in EAGD between a PTV-plan and a CMRO-plan without plan adaptation for a typical 167 
case is shown in figure 2. This case illustrates a higher dose to the target areas and a dose reduction 168 
to the organs at risk, particularly in the areas with high density gradients such as near bone and the 169 
esophagus. Similar dose differences were observed in the other cases. 170 
Robust optimization without plan adaptation 171 
The average EAGD for both the PTV-plan and CMRO-plan without plan adaptation are shown in table 172 
1 and figure 3. The D98% of the EAGD was significantly higher in the CMRO-plans compared to the 173 
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reference PTV-plans for the prophylactic CTV (ΔD98% = 1.5 Gy; 95%CI = 1.0-2.0 Gy; p = 0.002) and 174 
significantly lower dose to the ipsilateral parotid gland (ΔDmean = 2.8 Gy; 95%CI = 1.6-4.0 Gy; p = 175 
0.004), the inferior PCM (ΔDmean = 2.7 Gy; 95%CI = 0.4-5.0 Gy; p = 0.002) and the oral cavity (ΔDmean = 176 
0.7 Gy; 95%CI = 0.4-1.0 Gy; p = 0.004). The CMRO-plans also led to lower NTCP values for tube 177 
feeding dependence (ΔNTCP = 0.9%; 95%CI = 0.4-1.4%; p = 0.004) and xerostomia (ΔNTCP = 2.8%; 178 
95%CI = 1.5-4.1%; p = 0.006) compared the PTV-plans (table 1 and figure 4). 179 
The nominal dose distribution of the CMRO-plan showed significantly higher dose to the primary and 180 
prophylactic CTVs and significantly lower dose to the ipsilateral parotid gland, the inferior and 181 
superior PCM and the oral cavity compared to the PTV-plans. The NTCP values derived from the 182 
nominal dose were within 0.5% of the values calculated from the EAGD for both the CMRO-plan and 183 
PTV-plan. 184 
Robust optimization with plan adaptation 185 
CTV underdosage was not observed in the studied patients. However, the ΣNTCP  of 4/10 patients 186 
exceeded the 2.5% threshold after three weeks of treatment. Table 2 shows the results based on the 187 
EAGD derived from the adapted and non-adapted PTV-based and CMRO-based treatment 188 
simulations. In these four patients, the mean dose in the OARs was on average 1.1 (range: -1.1 – 3.1) 189 
Gy lower in the CMRO-plans than the PTV-based approach (table 2). The plan adaptation resulted 190 
into an additional 0.7 (range: -0.5 – 1.2) Gy dose reduction to the OARs. For these patients, the 191 
estimated NTCPs were on average reduced by 5.8% and 7.9% using an adapted PTV-plan and 192 
adapted CMRO plan, respectively.  193 
CBCT-based dose accumulation validation 194 
The absolute difference of the D98% of both CTVs derived from a set of weekly CBCTs and verification 195 
CTs was on average 0.5 Gy and the differences in NTCP values was on average 0.6% (Supplement 196 
Figure S.1). Comparing the dose from two different sets of weekly CBCTs, this difference was 0.1 Gy 197 
for the CTVs and 0.3% for the NTCP values. 198 
DISCUSSION  199 
We evaluated CMRO in VMAT of head and neck cancer patients, and assessed plan robustness using 200 
the estimated actual given dose. It was demonstrated that CMRO resulted in approximately 2 Gy 201 
lower mean dose to several OARs with similar or improved CTV coverage as compared to 202 
conventional PTV-based plans. On average, CMRO led to around a 2.3 Gy average dose decrease in 203 
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the parotids, pharyngeal muscle superior, cricopharyngeal muscle and the supraglottic larynx and a 204 
1.7 Gy increase of the D98% of the primary and elective CTVs. 205 
Other studies, albeit on different treatment sites, show similar results with CMRO in terms of OAR 206 
dose sparing. It was shown for CMRO in breast cancer patients that target coverage improved at 207 
identical or reduced OAR dose [6,23]. The agreement between the planned nominal dose and dose 208 
evaluated on the 4DCT was better for the CMRO-plans than the PTV-plans [6]. Archibald-Heeren et 209 
al. compared CMRO VMAT of lung cancer on a thorax phantom [24]. The authors found fewer 210 
maximum and minimum dose variations compared to other current treatment techniques such as 211 
internal target volume based planning as evaluated on a 4DCT [24]. Zhang et al. investigated the 212 
benefit of CMRO for five prostate cancer patients in which the CTV and OAR delineations were 213 
shifted inside the patient to create different scenarios [25]. Their method did not include a dose 214 
recalculation per scenario and accounted for internal target motion rather than patient positioning 215 
errors. They reported a mean dose reduction of 6.4% and 19.7% for the rectal and bladder walls, 216 
respectively. Previous studies on CMRO of proton therapy found larger benefits for CMRO, which 217 
was expected due to the inherent lack of dose invariance of the treatment modality [4,13,26].  218 
In terms of toxicity probabilities, the various NTCPs decreased approximately 1 – 3% for the CMRO 219 
plans as compared to the PTV-plans. The NTCP models were derived from planned dose 220 
distributions, whereas the NTCPs in this study were derived from the EAGD. Since the EAGD is 221 
potentially more directly related to toxicity than the planned nominal dose, this could lead to a slight 222 
underestimation of the improvement in toxicity probability. However, the NTCP values of the 223 
planned dose distribution were very similar to those from the EAGD (table 1). Therefore, we expect 224 
these results to be representative. 225 
We demonstrated that CMRO led to improved robustness compared to PTV-based optimization, at 226 
no expense of OAR dose. Other factors affecting the plan robustness are the magnitude of 227 
robustness shifts (or PTV margin) and the number of plan adaptations. In this study, we found, albeit 228 
on 4/10 patients, that CMRO led to an improved dose distribution when using plan adaptations after 229 
three weeks of treatment, indicating that CMRO can be used in combination with adaptive 230 
radiotherapy. Furthermore, it can be argued that CMRO may lead to fewer plan adaptations than 231 
PTV-based optimization. This was however not investigated.  232 
In this study, the EAGD was derived from dose calculations on daily acquired CBCTs that were 233 
mapped to the reference CT and accumulated. We acknowledge that the deformable image 234 
registration (required for dose mapping) introduces new unknown errors [27]. The dose calculation 235 
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was performed using a segmentation of the CBCT based on six tissue substitutes. Based on the 236 
comparison between dose accumulation using weekly CTs and weekly CBCTs, we estimated that the 237 
error introduced by CBCT-based dose mapping and accumulation were comparable. Furthermore, 238 
the same plan evaluation procedure was applied to the CMRO-plan and the PTV-plan. Therefore, the 239 
impact of the deformable image registration errors on the EAGD of both planning strategies was 240 
expected to be negligible. This was further confirmed by the observation that all statisticaly 241 
significant improvements of the CBCT-based EAGD also improved in the CT-based EAGD. 242 
Previous studies compared the robustness of CMRO and PTV-based optimization by shifting the 243 
planning CT without dose re-calculation, implicitly assuming dose invariance, which could lead to 244 
bias in favor of PTV-based optimization [5] or by systematic shifts with a dose recalculation could 245 
lead to bias in favor of CMRO [28]. By evaluating the dose on daily CBCTs, the EAGD accounts for 246 
geometrical variations and is very close to the actually given dose and not biased towards CMRO or 247 
PTV-based optimization. Furthermore, the accuracy of the CBCT-based dose calculation was 248 
evaluated against CT-based dose calculations of which the differences were smaller than the benefit 249 
of CMRO compared to PTV-based planning.. 250 
We did not observe any case with a CTV underdosage, even without plan adaptation. It is likely that 251 
the 5.0 mm CTV-PTV margin and a 5.0 mm robustness parameter were overly conservative. Since 252 
CMRO led to improved target coverage, fewer plan adaptations are expected. Alternatively, the 253 
robustness parameters could be decreased (i.e. <5.0 mm) such that the target coverage equals the 254 
coverage of the PTV-plans. This would potentially reduce OAR doses even further. Moreover, the 255 
robust objective functions were limited to CTVs only since the distribution of shifts for OAR further 256 
away from the treatment isocenter are variable. Taking different shifts for the OARs into account 257 
would be too computationally intensive, and will be part of ongoing work. 258 
The main conclusions of the presented work is that target coverage can be improved and OAR dose 259 
can be reduced by using CMRO as compared to PTV-based planning in VMAT of HNC patients. 260 
Secondly, we conclude that a mid-treatment course plan adaptation further reduces the dose to the 261 
OARs by approximately 1 Gy, albeit for a subgroup of patients. Lastly, we found that VMAT plan 262 
evaluation on CBCTs leads to similar conclusions with regard to the EAGD compared to weekly 263 
repeat CTs. This may potentially omit the need for repeat CTs for the purpose of plan evaluation if 264 
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TABLES AND FIGURES CAPTIONS 347 
Figure 1: Schematic representation of the workflow to calculate the estimated actually given dose.  348 
1: A deformable image registration is made for all 35 individual CBCTs to the planning CT. 2: The 349 
external of the planning CT is warped towards each CBCTs, the part of the external that is outside 350 
the CBCT’s field of view is overridden with a density of water. 3: The CBCTs are automatically 351 
segmented based on their CT value into air, lung, adipose, soft tissue, cartilage/bone and other (i.e. 352 
higher densities) to allow dose calculation. 4: The dose of the treatment plan is calculated on the 353 
segmented CBCTs resulting in a daily dose distribution. When a treatment plan-adaptation is 354 
considered, the first 15 fractions are calculated using the original treatment plan and the remaining 355 
20 fractions using the adapted treatment plan. 5: All doses are deformed to the planning CT using 356 
the registrations created in step 1. 6: The individual doses are summed resulting in the estimated 357 
actually given dose distribution. 358 
 359 
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Table 1: The average dosimetric parameters and NTCP values of the PTV-optimized and CMRO 361 
treatment plans 362 
Abbreviations: CI = conformity index; HI = homogeneity index; CMRO = Composite 363 
minimax robust optimization; PCM = pharyngeal constrictor muscle; EAGD: estimated 364 
actually given dose. The 95% confidence interval values are given between the brackets. *: 365 
statistically significant difference between de PTV-plan and cmRO-plan, using the 366 
Wilcoxon signed-rank test adjusted using Bonferonni’s correction for multiple testing. 367 
 Nominal Dose (N=10) EAGD (CBCT, N=10) EAGD (CT, N=10) 
 PTV-plan CMRO-plan PTV-plan CMRO-plan PTV-plan CMRO-plan 
Dmean of OARs (Gy)       
Ipsi Parotid 31.9 (27.3-37.1) 29.1 (25.0-33.9)* 32.7 (28.2-37.6) 29.8 (25.8-34.5)* 34.0 (29.3-39.2) 31.2 (26.8-36.0)* 
Contra Parotid  23.7 (19.0-29.2) 21.4 (16.8-26.0) 24.0 (19.3-29.4) 21.7 (17.3-26.3) 24.0 (19.3-29.5) 21.7 (17.3-26.3)* 
Submand. Right 53.4 (37.8-68.9) 53.3 (37.5-69.1) 53.2 (37.7-68.6) 53.0 (37.3-68.8) 53.5 (37.6-69.4) 53.3 (37.1-69.5) 
Submand. Left 57.8 (47.3-68.2) 58.3 (47.4-68.9) 57.9 (47.9-67.8) 58.4 (48.0-68.4) 58.1 (47.4-68.6) 58.6 (47.5-69.3) 
Inferior PCM 40.8 (31.0-53.1) 38.1 (28.1-50.9)* 41.4 (31.9-53.4) 38.7 (29.1-51.1)* 40.6 (31.1-52.6) 38.2 (28.6-50.6)* 
Superior PCM 51.5 (42.3-63.6) 50.7 (41.3-62.8)* 51.8 (42.6-63.9) 51.1 (41.7-63.2) 52.4 (43.3-64.3) 51.8 (42.5-63.7) 
Cricopharyngeus M. 23.2 (16.5-28.8) 21.0 (15.3-26.1) 22.6 (16.8-27.7) 20.8 (15.4-25.7) 23.2 (17.2-28.5) 21.1 (15.9-25.7)* 
Supraglottic Larynx 33.8 (22.8-43.1) 31.8 (20.6-41.4) 35.5 (24.2-44.5) 33.4 (22.0-42.9) 34.6 (23.4-44.3) 32.8 (21.3-42.8) 
Oral Cavity 40.5 (33.8-48.2) 39.7 (32.8-47.4)* 40.7 (34.0-48.4) 39.9 (33.1-47.6)* 40.8 (34.1-48.5) 40.1 (33.2-47.7)* 
Spinal cord (D2) 43.8 (39.2-48.2) 44.7 (40.1-48.8) 44.2 (40.2-48.0) 45.0 (40.9-48.6) 43.5 (38.9-47.9) 44.4 (39.8-48.4) 
       
Target coverage       
D98% CTVprimary (Gy) 69.2 (68.6-69.8) 71.3 (70.4-72.1)* 69.2 (68.6-69.8) 71.1 (70.1-72.0) 69.6 (69.0-70.2) 71.3 (70.3-72.2) 
D98% CTVprophylactic (Gy) 55.3 (52.6-57.6) 57.1 (54.4-59.4)* 55.0 (52.2-57.4) 56.5 (54.1-58.8)* 55.5 (52.8-57.8) 56.9 (54.4-59.0)* 
CI CTVprimary  0.52 (0.46-0.58) 0.53 (0.47-0.59) 0.52 (0.46-0.58) 0.53 (0.47-0.60) 0.52 (0.46-0.58) 0.53 (0.47-0.59) 
CI CTVprophylactic 0.51 (0.46-0.55) 0.51 (0.46-0.55) 0.50 (0.44-0.55) 0.50 (0.43-0.56) 0.51 (0.47-0.55) 0.51 (0.47-0.56) 
HI CTVprimary 0.92 (0.91-0.93) 0.92 (0.91-0.94) 0.92 (0.92-0.94) 0.92 (0.91-0.93) 0.93 (0.92-0.94) 0.92 (0.91-0.93) 
HI CTVprophylactic 0.74 (0.69-0.78) 0.75 (0.71-0.78) 0.72 (0.67-0.76) 0.72 (0.68-0.77) 0.72 (0.68-0.75) 0.72 (0.68-0.76) 
       
NTCPs (%)       
Tube feeding dep.     8.7 (4.6-11.7)     7.7 (4.0-10.4)*     8.9 (4.5-12.1)     8.0 (4.0-10.9)* 9.1 (4.6-12.4)     8.2 (4.1-11.2)* 
Grade 2-4 dysphagia 27.1 (21.3-34.1) 26.5 (20.6-33.4)* 27.3 (21.4-34.3) 26.7 (20.7-33.7) 27.6 (21.7-34.6) 27.1 (21.0-34.0) 
Xerostomia 56.1 (50.2-62.9) 53.1 (47.5-58.9)* 56.4 (50.7-63.2) 53.6 (48.1-59.3)* 56.4 (50.6-63.4) 53.6 (48.0-59.4)* 
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Table 2: The average dosimetric parameters and NTCP values of the non-adaptive and 370 
adaptive PTV-based and CMRO-based treatment simulations of four patients. 371 
Abbreviations as in table 1. Only four patients were studied in the adaptive setting. Due to 372 
the low sample size, no statistical test was performed. 373 
 EAGD Non-adapted plan (N=4) EAGD Adapted plan (N=4) 
 PTV-plan CMRO-plan PTV-plan CMRO-plan 
Dmean of OARs (Gy)     
Ipsi Parotid 27.3 (23.6-29.7) 24.3 (20.0-27.1) 24.3 (20.0-27.1) 24.8 (19.9-28.0) 
Contra Parotid  25.5 (23.2-27.1) 22.3 (20.3-23.7) 22.3 (20.3-23.7) 21.7 (19.0-23.5) 
Submand. Right 62.3 (55.4-67.2) 63.3 (56.5-68.1) 63.3 (56.5-68.1) 62.4 (55.7-67.1) 
Submand. Left 67.4 (66.8-68.3) 68.5 (66.8-70.4) 68.5 (66.8-70.4) 67.6 (65.8-69.2) 
Inferior PCM 36.4 (21.2-47.1) 34.0 (19.4-44.5) 34.0 (19.4-44.5) 33.0 (18.1-43.5) 
Superior PCM 60.4 (57.9-62.2) 60.0 (57.2-61.8) 60.0 (57.2-61.8) 59.3 (57.1-60.8) 
Cricopharyngeus M. 23.0 (18.9-25.9) 21.8 (17.8-24.9) 21.8 (17.8-24.9) 21.2 (17.5-23.8) 
Supraglottic Larynx 40.8 (21.6-53.9) 39.7 (18.8-54.1) 39.7 (18.8-54.1) 38.5 (16.9-53.1) 
Oral Cavity 47.5 (42.0-51.1) 47.0 (41.0-51.0) 47.0 (41.0-51.0) 46.2 (40.2-50.3) 
Spinal cord (D2) 48.9 (47.5-49.8) 49.9 (47.8-51.3) 49.9 (47.8-51.3) 48.9 (46.3-50.5) 
     
Target coverage     
D98% CTVprimary (Gy) 53.7 (52.9-54.5) 55.7 (54.8-56.6) 55.7 (54.8-56.6) 54.3 (51.9-57.2) 
D98% CTVprophylactic (Gy) 69.1 (68.4-69.6) 71.7 (70.6-72.5) 71.7 (70.6-72.5) 71.1 (69.7-72.1) 
CI CTVprimary  0.53 (0.48-0.59) 0.53 (0.48-0.59) 0.53 (0.48-0.59) 0.55 (0.50-0.60) 
CI CTVprophylactic 0.52 (0.50-0.54) 0.52 (0.50-0.54) 0.52 (0.50-0.54) 0.53 (0.51-0.55) 
HI CTVprimary 0.92 (0.91-0.93) 0.92 (0.92-0.92) 0.92 (0.92-0.92) 0.93 (0.93-0.94) 
HI CTVprophylactic 0.67 (0.64-0.72) 0.69 (0.64-0.74) 0.69 (0.64-0.74) 0.67 (0.59-0.78) 
     
NTCPs (%)     
Tube feeding dep. 14.1 (7.0-19.1) 12.7 (6.2-17.3) 12.7 (6.2-17.3) 12.2 (5.9-16.5) 
Grade 2-4 dysphagia 32.9 (28.8-35.7) 32.5 (28.1-35.4) 32.5 (28.1-35.4) 31.7 (27.6-34.4) 
Xerostomia 58.4 (55.6-60.5) 54.4 (51.8-56.2) 54.4 (51.8-56.2) 53.6 (50.1-55.9) 
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Figure 2: Differences in estimated actually given dose for a PTV optimized and a robustly 376 
optimized VMAT treatment plan: Typical case 377 
a) Difference in estimated actually given dose distribution. b) Dose volume histogram of the 378 
estimated actually given dose for both treatment plans.   379 
 380 
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Figure 3: Estimated actually given dose for PTV optimized and robustly optimized VMAT treatment 382 
plans (n=10).  383 
Each scatter plot represents a different dose parameter. The x position of each data point 384 
corresponds to its value of the PTV optimized plan and its y position to its value of the robustly 385 
optimized plan. Therefore, data points below the diagonal indicate a lower value in the robustly 386 
optimized plan than in the PTV optimized plan. Data points shown as circles represent the planned 387 
nominal dose and diamond shapes represent the estimated actually given dose. 388 
 389 
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Figure 4: Estimated normal tissue complication model outcome for PTV optimized and robustly 391 
optimized VMAT treatment plans (n=10).  392 
Each scatter plot represents a NTCP model. The x position of each data point corresponds to its value 393 
of the PTV optimized plan and its y position to its value of the robustly optimized plan. Therefore, 394 
data points below the diagonal indicate a lower value in the robustly optimized plan than in the PTV 395 
optimized plan. Data points shown as circles represent the planned nominal dose and diamond 396 




Figure S.1: Average absolute differences in estimated actually given dose of a PTV optimized 399 
treatment plan using verification CTs and using CBCTs of the next fraction (CBCT -- rCT) or using 400 
weekly CBCTs and CBCTs of the next fraction (CBCT -- CBCT) (n=10).  401 
The CBCT -- rCT differences are the result of a systematic difference in dose calculation method and 402 
interfraction movement. The CBCT -- CBCT differences are only the result of interfraction movement. 403 
Error bars represent the standard error of the mean.  404 
*: Wilcoxon sign rank test p < α with an α of 0.05 adjusted using Bonferroni’s correction for multiple 405 
testing 406 
 407 
